This analysis evaluated HbAu adjustnd hypoglycemia risk with darine venus neutral protamine Hagedom(NM0 over year study hn patients with Type 2 diabetes melimas(T20My clinical significance was asessed mumber ineded to barm(NNIn demonstrat e the risk of one g at least one Methods Individual patient-level data for symptomatic documented bypoglyoemia and HhAra values from a 5-year randomized study comparing once daily darcine(n 513) with twice-daily NpH(n 504) were analyzed Symptomatic hypoglycemia was categorized according to concurrent sell monitorinr blood duoose levels and Dend for assistance Hypoglyoemic events per patient-year as a function of HbAt, were firted by negative binomial regression using treatment and HbAheat endpoint as independent variables. An estimate of NNH was derived from logistic regression models. Results: The cumulative number of symptomatic hypoglycemia events was consistently lower with turgine compared with NPH over 5 years. Compared with twice-daily NPH, once dailygdargine treatment resulted significantly lower adjusted odds ratios(OR) for all daytime hypoglyoemia